WHY MEET AGENDIA AT SAN ANTIONIO 2026?
Genomic insights for better decisions
in early-stage breast cancer
NEW DATA TO BE PRESENTED
New MammaPrint + BluePrint Data at San Antonio 2026
Explore research on genomic risk and molecular subtyping in early-stage breast cancer.
Excellent Long Term Outcomes Irrespective of Chemotherapy Use or Age for Clinically High and Genomically UltraLow Risk Early Breast Cancer in the MINDACT trial
Molecular subtyping, pathologic complete response, and immune profiling of germline BRCA1/2-mutated HR+/HER2− breast cancer in the FLEX study
Genomic Characterization of ER-Low Breast Cancer in the Real-World FLEX Registry: Distinct Biology and Outcomes Defined by 70-Gene Recurrence Risk and 80-Gene Molecular Subtyping assays
80-gene molecular subtyping assay informs neoadjuvant platinum-based treatment selection and predicts high pathologic complete response in HR+/HER2− breast cancer
Association of CD47 expression with the 70-gene genomic risk assay, 80-gene molecular subtyping, and clinical outcomes in early breast cancer
ABOUT
Breast Cancer Research in San Antonio
From December 8–11, 2026, clinicians, researchers, and patient advocates from around the world will gather in San Antonio to exchange perspectives on breast cancer research and care.
Connect with Agendia to discuss the role of genomic testing in early-stage breast cancer. Meet with our team to learn more about MammaPrint®, BluePrint®, and our ongoing research.
This page is independently managed by Agendia and provides information about our participation in 2026 SABCS®. It is not sponsored or endorsed by the symposium organizers.
THE MAMMAPRINT + BLUEPRINT TEST SUITE
Analyze over a hundred relevant genes at once.
With the additional results of BluePrint, our molecular subtyping test, physicians gain an even broader genomic profile. From just one tumor block, you can interrogate over 150 genes containing information on a tumor’s level of aggression and potential for growth. These insights will serve as an essential resource for guiding your pre- and post-operative treatment strategies.